SEC Form 4 · accession 0001104659-18-050188
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rafael Amado
Officer — President, R & D
Period of report
Aug 6, 2018
Accepted (ET)
Aug 7, 2018 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Ordinary SharesF1,F2,F3 | $0.0013 | Aug 6, 2018 | A | 678,720 | A | — | — | Ordinary Shares | 678,720 | 678,720 | D |
Explanation of responses
- F1The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.29679 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- F2Exercisable as to 169,680 Ordinary Shares on August 6, 2019 and will be exercisable as to the remainder in annual installments of 169,680 Ordinary Shares on the sixth of each August from August 6, 2020 through August 6, 2022.
- F3The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.